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Abstract 
Expression of synuclein-gamma (SNCG) protein is 
elevated in the advanced stages of many types of 
cancers, including breast, ovarian, lung, gastric, 
liver, esophagus, colon, prostate and others.  
In breast carcinoma, SNCG is causatively linked to 
stimulated proliferation, metastasis and drug 
resistance.  
A clinical follow-up study indicates that patients 
with an SNCG-positive breast cancer have a 
significantly shorter disease-free survival and 
overall survival than patients with SNCG-negative 
tumors.  
Overexpression of SNCG compromises normal 
mitotic checkpoint controls, resulting in 
multinucleation as well as faster cell growth.  
SNCG has also been shown to promote invasion 
and metastasis in in vitro assays as well as in 
animal models. SNCG overexpression also 
interferes with drug-induced apoptotic responses. 
Expression of SNCG in cancer cells results in a 
more malignant phenotype with increased cell 
motility, enhanced transcriptional activity of steroid 
receptors and accelerated rate of chromosomal 
instability.  
Two closely located AP1 binding sites residing in 
the first intron of the SNCG gene are important 
regulators of the promoter activity. Other factors 
regulating SNCG expression are methylation-
demethylation of exon and post-transcriptional 
regulation by microRNAs. 
Keywords 
Invasion, metastasis, cancer, tumorigenesis, 
transcriptional regulation, microRNA 
Identity 
Other names: BCSG1, gamma-synuclein, 
PERSYN, PRSN, Synoretin 
HGNC (Hugo): SNCG 
Location: 10q23.2 
Note 
Synuclein-gamma is a member of the synuclein 
family of proteins which are believed to be 
involved in the pathogenesis of neurodegenerative 
diseases. High levels of SNCG have been identified 
in several types of cancer suggesting the association 
of its overexpression and cancer development. 
DNA/RNA 
Description 
Human SNCG gene consists of five exons that span 
about 5 kbp. The intron 1 contains two closely 
located AP1 recognition sequences. Deletion of 
these motifs greatly diminished the SNCG promoter 
activity, suggesting that AP1 is an important 
transactivator for SNCG transcription SNCG 
transcription is primarily controlled by regulatory 
sequences located in intron 1 and exon 1 and in a 
lesser extent by 5' flanking region. Synuclein 
expression is regulated predominantly at the level 
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of SNCG gene transcription, SNCG mRNA 
stability and by micro-RNA (miRs). 
Protein 
Description 
Encoded by human SNCG gene (synuclein family), 
the highly conserved 127-amino acid 13 kD 
cytoplasmic gamma-synuclein is similar to two 
other members of the family, alpha-synuclein and 
beta-synuclein. The gamma-synuclein protein is the 
least conserved of the synuclein proteins. The 
human gamma-synuclein is 87.7% and 83.8% 
identical to the mouse and rat proteins, respectively, 
which are 4-amino acids shorter. For all three 
members of the family the region of highest 
homology is the amino-terminal region. The 
synuclein proteins contain several repeated domains 
that display variations of a KTKEGV consensus 
sequence. This motif, repeated six to seven times in 
the amino-terminal portion of the protein, is 
reminiscent of the alpha-helical domains of the 
apolipoproteins and suggests lipid binding 
properties. The very high conservation between 
species for a specific repeated domain of a 
particular protein suggests that the repeated 
domains have arisen from the duplication of a 
single domain within an ancestral synuclein gene. 
Later, this ancestral gene may have undergone 
successive duplications to give rise to the three 
synuclein genes in which the repeated domains may 
still be able to diverge. The third domain, however, 
remained absolutely identical, KTKEGV, in all 
genes throughout all species. A similar type of 
domain is present in proteins of the rho family. 
However, as of today, the role of these domains 
remains unknown. 
Expression 
Mammalian gamma-synuclein was first identified 
as the so-called breast cancer-specific gene 1 
(BCSG1) in a high-throughput direct differential-
cDNA-sequencing screen for markers of breast 
cancer. Northern blot analysis showed that the gene 
is principally expressed in the brain, particularly in 
the substantia nigra. The protein is expressed in the 
peripheral nervous system, mainly in primary 
sensory neurons, sympathetic neurons, and motor 
neurons. A high level of synuclein gamma was also 
detected in several types of tumors, and in the 
olfactory epithelium. A sequence dubbed synoretin 
was independently isolated from ocular tissues in a 
screen for novel proteins regulating 
phototransduction and is now thought to represent 
the bovine ortholog of gamma-synuclein. SNCG is 
expressed in brain, heart, skeletal muscle, ovary, 
testis, colon, spleen, pancreas, kidney and lung. 
MicroRNAs (miRs) are implicated in the regulation 
of SNCG expression. 
Localisation 
The three human synuclein genes are expressed in 
the thalamus, the substantia nigra, the caudate 
nucleus, and the amygdala. Only gamma-synuclein 
appears strongly expressed in the subthalamic 
nucleus. Although gamma-synuclein is not present 
in senile plaques, Lewy bodies or neurofibrillary 
tangles, a high level of gamma-synuclein 
immunoreactivity is detectable in dot-like structures 
and other deposits which are characteristic lesions 
in the brains of patients with neurodegenerative 
diseases, as well as in the retina and optic nerve. 
SNCG mRNA and gamma-synuclein protein were 
also detected in unstimulated and 
phytohaemagglutinin (PHA)-stimulated cultured 
lymphocytes from peripheral blood of normal 
donors. It has been shown previously by in situ 
hybridization that SNCG/BCSG1 mRNA is not 
expressed in normal adult breast tissue, but high 
levels of this mRNA are present in advanced 
infiltrating breast tumours. In paraformaldehyde 
fixed cells, SNCG displayed punctuate cytoplasmic 
staining, a pattern that is usually associated with 
markers of the endoplasmic reticulum or vesicular 
structures. 
Function 
The normal cellular function of gamma-synuclein is 
as yet unclear, but interestingly exogenous 
expression of the protein increases the invasive and 
metastatic potential of breast tumors. The highly 
conserved N-terminal region is known to be 
important for the lipid interactions of the synucleins 
and the highly acidic C-terminal region has been 
suggested to possess chaperone-like activity, to 
regulate the aggregation of synucleins and to 
mediate protein-protein interactions. It seems that 
gamma-synuclein plays a role in neurofilament 
network integrity and may modulate axonal 
architecture, also, it may increase the susceptibility 
of neurofilament-H to calcium-dependent proteases 
and may also modulate the keratin network in skin. 
Phosphorylation by GRK5 appears to occur on 
residues distinct from other kinase target residues. 
Synuclein gamma is likely involved in the 
pathogenesis of neurodegenerative and ocular 
diseases, for example, glaucoma and SNCG is 
expressed at very high level in advanced infiltrating 
breast cancer. The dual role of SNCG in 
neurodegeneration and malignancy could involve 
common mechanisms. Changes in organization of 
the cell cytoskeleton are among the most prominent 
characteristics of both processes. The involvement 
of gamma-synuclein in regulating neurofilament 
network integrity raises the possibility that it may 
also affect the intermediate filament network in 
malignant breast epithelial cells. In addition, 
gamma-synuclein regulates the level of expression 
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of several genes, for example matrix 
metalloproteinases 2 and 9 (MMP-2 and MMP-9). 
Gamma-synuclein is readily oxidized at 
methionine-38 and after oxidation it aggregates and 
induces the aggregation of alpha-synuclein.  
The binding of gamma-synuclein to phospholipase 
C β2 (PLCβ2) results in inhibition of enzymatic 
activity and therefore may regulate the intracellular 
level of second messenger phosphatidylinositol 4,5 
bisphosphate (PI(4,5)P2).  
Gamma-synuclein is a novel regulator of lipid 
metabolism in adipocytes and the deficiency of this 
protein has a significant effect on whole body 
energy expenditure. 
Homology 
There are currently almost 200 DNA and protein 
sequences in the sequence databases with high 
homology to the synuclein gene or protein.  
All synuclein sequences available to date from 
Homo sapiens, Mus musculus, and Rattus 
norvegicus can be assigned to three distinct protein 
groups: alpha beta and gamma-synuclein. Synuclein 
proteins have also been identified in other 
organisms: synelfin is the alpha-synuclein ortholog 
in Serinus, phospho-neuroprotein 14 (PNP14) is the 
beta-synuclein ortholog in Bos taurus, and the first 
synuclein protein described in Torpedo californica 
corresponds to the human gamma-synuclein. 
Interestingly, synucleins are identified only in 
vertebrate and no homologous proteins have been 
revealed in invertebrate or lower organisms.  
Each of the three family members is composed of 
an N-terminal lipid-binding domain, containing a 
series of 11-residue imperfect repeats, and an acidic 
C-terminal domain.  
Among the human family members, gamma-
synuclein 50% identical and 74% homologous to 
alpha-synuclein and 47% identical and 66% 
homologous beta-synuclein.  
The highly conserved N-terminal region is known 
to be important for the lipid interactions of the 
synucleins and the highly acidic C-terminal region 
has been suggested to possess chaperone-like 
activity, to regulate the aggregation of synuclein 
and to mediate protein-protein interactions.  
The very high degree of conservation in the lipid-
binding N-terminal domains of all three synucleins 
strongly suggests that both beta and gamma-
synuclein like alpha-synuclein bind to lipid 
membranes and adopt a highly helical structure. 
Nevertheless, differences in the sequences of the 
three proteins in both their central parts and C-
terminal domains must be responsible for those 
differences that do exist in their individual 
functions, as well as for their different roles in 
disease. 
 
Mutations 
Note 
No tumor-specific mutations of the SNCG gene 
were found in breast tumors and tumor cell lines, 
but two linked polymorphisms in the coding region 
were detected, both in mRNA and in exons III and 
IV of the gene from G243C and T377A.  
These results reflect the absence of two G--A (and 
consequently Glu--Lys) in tumor cell lines, tumors 
and control tissues.  
The above mentioned two linked polymorphic sites 
discriminate two alleles of the human persyn gene. 
The frequencies of the two alleles were the same in 
genomes of breast cancer and normal cells (20% 
G243/T377 and 80% C243/A377).  
Both alleles are transcriptionally active and are 
expressed with similar efficiency in heterozygotes. 
Epigenetics 
Sequence analysis identified a CpG island in exon 1 
of SNCG that contains 15 CpG sites, covering the 
region -169 to +81, relative to the translation start 
codon. CpG sites within the CpG island and its 
vicinity were partially and heterogeneously 
methylated in SNCG-negative breast cancer cell 
lines but unmethylated in SNCG-positive cells. 
SNCG expression correlates with complete 
demethylation of the exon 1 region. Specific 
methylation at the CpG sites 2, 5, 7, and 10-15, was 
sufficient to block the expression of SNCG gene in 
breast cell culture. Genomic sequencing and 
methylation-specific PCR assays have shown that 
SNCG CpG island is fully methylated in normal 
tissues of liver, esophagus, prostate, cervix, 
stomach, colon, and lung, but only partially 
methylated in breast tissue. Tumors from these 
tissues contain completely demethylated SNCG. 
Universal loss of the epigenetic control of SNCG 
gene expression in tumors and further 
demonstrating that the demethylation of SNCG 
CpG island is primarily responsible for the aberrant 
expression of SNCG protein in cancerous tissues 
have suggested an important role of gamma-
synuclein-related epigenectic events in various 
malignancies. Reactivation of SNCG gene 
expression by DNA demethylation is a common 
critical contributing factor to malignant progression 
of many solid tumors and its expression in primary 
carcinomas is an effective molecular indicator of 
distant metastasis. 
Implicated in 
Note 
The possible involvement of gamma-synuclein in 
tumorigenesis first came to light when a gene  
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named BCSG1 (breast cancer-specific gene 1) was 
shown to be overexpressed in advanced infiltrating 
carcinoma of the breast. In fact, BCSG1 and 
gamma-synuclein appear to be the same protein. 
SNCG protein is highly expressed in diversified 
cancer types, including the female hormone-
sensitive cervical and breast cancers, male 
hormone-sensitive prostate cancer, four cancer 
types of the digestive system, and lung cancer. 
These cancers are currently the leading cause of 
mortality in both men and women. How SNCG 
induces disease progression in different cancer 
types remains elusive. Oncogenic activation of 
gamma-synuclein contributes to the development of 
breast and ovarian cancer by promoting tumor cell 
survival under adverse conditions and by providing 
resistance to certain chemotherapeutic drugs. 
Overexpression of gamma-synuclein leads to 
constitutive activation of extracellular signal-
regulated protein kinases (ERK1/ERK2) and down-
regulation of c-Jun N-terminal kinase 1(JNK1) in 
response to environmental stress signals. Gamma-
synuclein is found in a wide variety of transformed 
cells and its overexpression leads to a significant 
increase in proliferation, motility, invasiveness and 
metastasis. Cells expressing gamma-synuclein are 
significantly more resistant to the chemotherapeutic 
drugs paclitaxel and vinblastine as compared with 
the parental cells. Activation of JNK1 and its 
downstream caspase-3 by paclitaxel or vinblastine 
is significantly down-regulated in gamma-
synuclein-expressing cells, indicating that the 
apoptosis pathway activated by vinblastine or 
paclitaxel is blocked by gamma-synuclein. In breast 
cancer cells, SNCG has been shown to act as a 
chaperon for estrogen receptor and stimulate 
estrogen receptor-a signaling pathway that leads to 
cell proliferation. On the other hand, the inhibitory 
effects of SNCG on mitotic checkpoint function are 
mediated through the mitotic checkpoint kinase 
BubR1 and are independent of the expression status 
of estrogen receptor-alpha. The inhibitory effects of 
SNCG on mitotic checkpoint can be overthrown by 
enforced overexpression of BubR1 in SNCG-
expressing cells. SNCG intracellularly associates 
with BubR1 together. This observation suggests 
that SNCG expression compromises the mitotic 
checkpoint control by inhibition of the normal 
function of BubR1, thereby promoting genetic 
instability, a recognized and important contributing 
factor in tumorigenesis. Because all synucleins 
have chaperone-like activities, they may interact 
with different proteins in different cellular 
background. Identifications of specific cellular 
targets of SNCG in different tumor types will 
provide insight to delineate its oncogenic functions 
in human malignancies. 
Breast cancer 
Note 
Patients whose tumors expressed SNCG had a 
significantly shorter disease-free survival and 
overall survival. They also had a high probability of 
death when compared with those whose tumors did 
not express SNCG. Multivariate analysis 
demonstrated that SNCG is an independent 
predictive marker for recurrence and metastasis in 
breast cancer progression. SNCG is expected to be 
a useful marker for breast cancer progression and a 
potential target for breast cancer treatment. In one 
study it has been show that responses of 12 breast 
cancer cell lines to paclitaxel-induced mitotic arrest 
and cytotoxicity highly correlated with SNCG 
expression status. SNCG-positive cells exhibited a 
significantly higher resistance to paclitaxel-induced 
mitotic arrest than SNCG-negative cells. Down-
regulation of SNCG expression directly increased 
the effectiveness of anti-microtubule drug-induced 
cytotoxicity in breast cancer cells without altering 
cell responses to doxorubicin. These new findings 
suggest that SNCG expression in breast carcinomas 
is probably a causal factor contributing to the poor 
patient response to paclitaxel treatment. 
Ovarian cancer 
Note 
Several studies indicated that SNCG expression 
was not detectable in normal ovarian epithelium but 
was highly expressed in the vast majority of 
advanced staged ovarian carcinomas. Eighty-seven 
percent of ovarian carcinomas were found to 
express at least 1 type of synuclein, and 42% 
expressed all 3 synucleins (alpha, beta, and gamma) 
simultaneously. Highly punctate gamma synuclein 
expression was also observed in 20% of 
preneoplastic lesions of the ovary, including 
epithelial inclusion cysts, hyperplastic epithelium, 
and papillary structures, suggesting that synuclein 
gamma up-regulation may occur early in the 
development of some ovarian tumors. 
Demethylation is an important event in abnormal 
synuclein-gamma expression. The methylation 
pattern in ovarian cancer cells is different from that 
in breast cancer cells. In one of the studies that 
examined SNCG-nonexpressing ovarian cancer 
cells, all of the CpG sites were completely 
methylated instead of selective methylation at 
certain sites shown in breast cancer cells, thereby 
suggesting a tissue-specific methylation pattern. 
Recent studies indicated that the detection of SNCG 
mRNA in tumor-positive tumors was strongly 
associated with demethylation or hypometylation of 
SNCG gene. Methylation status was not correlated 
with FIGO stage or histological type of tumor. 
Tumor grading was strongly associated with  
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methylation status but due to relatively small group 
of studied samples (43 cases) this observation 
requires further confirmation.  
Another interesting observation was that in 21% of 
samples both products of amplification were 
present and all these cases were SNCG mRNA-
positive.  
This observation could suggested that partial 
methylation of SNCG probably does not influence 
on synuclein expression in ovarian cancer tissue. 
Comparison of the methylation status of SNCG and 
the expression of synuclein-gamma in breast and 
ovarian cancer cells lines in another study indicated 
a strong correlation between hypomethylation of 
the CpG island and SNCG expression in cancer cell 
lines.  
The methylation pattern in ovarian cancer cells was 
different from that in breast cancer cells.  
The analyzed CpG sites in ovarian cancer cells 
were all methylated in contrary to a selective 
methylation at certain sites shown in breast cancer 
cells, thereby suggesting a tissue-specific 
methylation pattern. Moreover, when exon 1 was 
partially and heterogeneously methylated, then 
SNCG expression in breast cancer cells was not 
detected. 
Lung cancer 
Note 
SNCG is not expressed in normal lung tissues, but 
it is highly expressed in lung tumors. It has been 
demonstrated that cigarette smoke extract (CSE) 
has strong inducing effects on SNCG gene 
expression in lung cancer cells through 
demethylation of SNCG CpG island. CSE treatment 
also augments the invasive capacity of cells in an 
SNCG-dependent manner. These new findings 
demonstrate that tobacco exposure induces the 
abnormal expression of SNCG in lung cancer cells 
through downregulation of expression levels of 
DNA methyltransferases. 
Gastric cancer 
Note 
For the gastric cancer cell lines, SNCG mRNA 
expression strongly correlated with demethylation 
of SNCG exon 1 CpG islands. Whereas SNCG was 
not expressed in non-neoplastic gastric mucosal 
tissues obtained at autopsy, partial demethylation 
was present in these tissues. Demethylation occurs 
before malignant transformation and that only 
partial demethylation does not result in up-
regulated SNCG mRNA expression. Thus, it 
appears that partial SNCG demethylation can occur 
in normal gastric mucosa, which then extends in 
some cases to become to fully demethylated, 
resulting in up-regulated SNCG mRNA expression. 
Esophageal cancer 
Note 
The examination of the serum γ-synuclein levels of 
patients with gastrointestinal and esophageal 
squamous cell carcinomas, benign disease and 
healthy controls by a sandwich ELISA 
demonstrated a positive correlation between serum 
γ-synuclein and the development of these types of 
cancer. From this study a conclusions was put 
forward that serum γ-synuclein is a promising 
diagnostic biomarker for early detection of 
gastrointestinal and esophageal cancer. Serum γ-
synuclein SNCG may play an important role in 
invasion, infiltration and apoptosis of esophageal 
cancer and serve as target spots in the targeted 
therapy of esophageal cancer. However, the 
analysis of expression pattern of SNCG in another 
study including 27 cases of esophageal cancer 
(ESC) demonstrated that it is downregulated in 16 
out of 27 cases of ESC. Overexpression of SNCG 
in ESC 9706 cell line has shown that the ectopic 
expression of SNCG in ESC cell line inhibits cell 
growth in dish and colony formation in soft agar. 
Therefore, unlike breast and ovarian cancers, a 
reversed correlation between SNCG expression and 
ESC development was found, which led to a 
hypothesis that SNCG may play a role of a tumor 
suppressor in the development of human ESC. 
Prostate cancer 
Note 
A strong association between SNCG expression and 
prostate cancer development is found. By 
performing genomic sequencing and methylation-
specific PCR assays, an inclusive demethylation of 
CpG sites within the CpG island of SNCG gene in 
prostate cancer samples was established. These 
results suggest a loss of the epigenetic control of 
SNCG gene expression in tumors and demonstrate 
that the demethylation of SNCG CpG island is 
primarily responsible for the aberrant expression of 
SNCG in prostate cancerous tissues. A conclusion 
is drawn that that reactivation of SNCG gene 
expression by DNA demethylation is a common 
critical contributing factor to malignant progression 
of tumors and its expression in primary carcinomas 
is an effective molecular indicator of distant 
metastasis. Therefore, the methylation status of 
SNCG gene can be used as a sensitive molecular 
tool in early detections of tumorigenesis. Silencing 
SNCG by siRNA in LNCaP cells contributes to the 
inhibition of cellular proliferation, the induction of 
cell-cycle arrest at the G1 phase, the suppression of 
cellular migration and invasion in vitro, as well as 
the decrease of tumor growth in vivo with the 
notable exception of castrated mice. SNCG is a 
novel androgen receptor (AR) coactivator.  
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It interacts with AR and promotes prostate cancer 
cellular growth and proliferation by activating AR 
transcription in an androgen-dependent manner. 
Endometrial cancer 
Note 
SNCG expression is associated with poor outcome 
in endometrial adenocarcinoma. There is a positive 
association between SNCG expression and tumor 
grade, tumor stage, type II carcinomas, deep 
myometrial invasion and lymphovascular invasion. 
A correlation between SNCG and adverse 
outcomes, such as shorter overall survival and 
disease free survival is found. 
The expression level of SNCG in endometrioid 
endometrial carcinoma is closely associated with 
International Federation of Gynecology and 
Obstetrics (IFGO) stages, the depth of myometrial 
invasion and lymph nodes metastases (p 
SNCG is considered a useful marker for 
endometrioid endometrial carcinoma invasion, 
metastasis and prognosis in endometrioid 
endometrial carcinoma. 
Gallbladder cancer 
Note 
SNCG is highly expressed in human gallbladder 
cancer, and its abnormal expression is associated 
with tumor aggressiveness. SNCG gene silencing in 
NOZ cells inhibited cell growth, colony formation, 
and invasion. In addition, it directly increased the 
effectiveness of paclitaxel in inducing G2/M cell-
cycle arrest and cell apoptosis. A decrease in tumor 
growth and weight was found in mice injected with 
SNCG-silenced NOZ cells. Together, these findings 
suggest that SNCG plays an important role in the 
progression of human gallbladder cancer. 
Colon cancer 
Note 
Abnormal expression of SNCG protein has been 
demonstrated in colon cancer. SNCG predicts poor 
clinical outcome in colon cancer with normal levels 
of carcinoembryonic antigen (CEA). SNCG levels 
in colon adenocarcinoma were closely associated 
with intravascular embolus and tumor recurrence 
but independent of preoperative serum CEA levels. 
SNCG expression was an independent prognostic 
factor of a shorter disease-free survival and overall 
survival (P < 0.0001). SNCG is a new independent 
predicator for poor prognosis in patients with colon 
adenocarcinoma, including those with normal CEA 
levels. Combination of CEA with SNCG improves 
prognostic evaluation for patients with colon 
adenocarcinoma. 
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